XTerra Columns Bricgure - Waters Corporation · XTerra® MS XTerra ®MS C 18 and MS C 8 columns...

Isolation/Purification

Drug Development

Drug Discovery

The Most Successful Column in Over 30 Years of Stationary Phase Technology

The universal acceptance by pharmaceutical scientists in drug discovery, method development and isolation and purification has

enabled XTerra® columns to become the fastest selling and most successful column product in the world of chromatography. The reason:

the enabling science of Hybrid Particle Technology. Drug discovery scientists benefit from the DMSO injection-resistance of the rugged

XTerra® particle. Method development scientists are able to operate at whatever pH is necessary for optimal selectivity due to XTerra®

columns’ wide pH range. Isolation and purification scientists can load up to 60x more material per injection because of the high mass

loading capacity of XTerra® columns.

XTerra® Columns

2

For over 30 years, scientists have been forced to work within certain boundaries when performing HPLC separations. Restrictions on speed, resolution, pH, temperature, and loading capacity

were imposed upon the chromatographer by limitations of the stationary phase material. The patented* Hybrid Particle Technology of XTerra® columns allows chromatographers to break these

boundaries and realize the full potential of their analytical and preparative separations.

In Hybrid Particle Technology, one out of every three silanols is replaced with a methyl group during synthesis. This hydrophobicity is distributed throughout the entire structure of the particle

backbone. The result is a rugged hybrid (inorganic/organic) particle that can be operated at high speeds, high temperatures, and high pH. The presence of 33% fewer residual silanols (after

endcapping and bonding) also means that XTerra® columns give exceptionally sharp, high-efficiency peaks for basic compounds.

*US Patent No. 6,686,035 B2

Traditional Silica Manufacturing Process

Traditional versus XTerra® Manufacturing Process

OH

SiO O

OO

SiO

OH

OSi

O

OH

OSi

O

OO

Si

OSi

O

OH

SiOH

O

Si

OO

Si

Si

Si OH

O O

Si OO

Si

SiSi

Si

Si

Si

SiHO

Si

SiO

O

SiO

O

Si O

HO O

SiSi

Si

SiOHO

O

Si

SiO

HO

OSi

O

HO

HO

Si

Si

OSi

O

OH

O

Si

Si

OH

O O

O

SiOH

OO

Si

Si

Si OH

OO

SiO

OSi OH

O

Si

Si

SiSi

OH

SiO O

O

SiOO

SiO

OHO

Si O

OO

Si

OSi

O

OH

SiO

Si

O

O

O

Si

Si

Si

O O

Si OO

Si

SiSi

Si

Si

Si

Si

HOSi

O

SiO

O

SiO

O

Si O

HO O

SiSi

Si

SiO

O

Si

SiO

HO

OSi

O

HOSi

Si

OSi

O

OHO

Si

Si

OH

O

O

SiOO

Si

Si

Si OH

OO

SiO

OSi OH

O

Si

Si

SiSiH3C

H3C CH3

H3C

H3C

H3C

CH3CH3

H3C

CH3

CH3

CH3

H3C

H3C

CH3

CH3

Methylpolyethoxysilane(MPEOS)

Tetraethoxysilane(TEOS)

Methyltriethoxysilane (MTEOS)

+2

OEt

SiO O

EtO

SiOEt

OEt

OEtSi

OEt

EtO

EtOEtO

SiEtO OEt

EtO

EtO

SiEtO OEt

EtO

SiO O

EtO

Si

OEt

OEtOEt

Si

OEt

EtO

EtO

SiEtO OEt

EtO

CH3 H3C

Unbonded Silica Particle

Polyethoxysilane(PEOS)

Tetraethoxysilane (TEOS)

+2

OEt

SiO O

EtO

SiOEt

OEt

OEtSi

OEt

EtO

EtOEtO

SiEtO OEt

EtO

EtO

SiEtO OEt

EtO

SiO O

EtO

Si

OEt

OEtOEt

Si

OEt

EtO

EtO

SiEtO OEt

EtO

CH3 H3C

Bonded and Endcapped XTerra® Particle• Highest, most homogenous coverage• 1/3 less silanols• Superior peak shape• pH range 1-12

UnbondedXTerra®

Particle

Bonded and Endcapped Silica Particle• Lower surface coverage• Poor peak shape for bases• pH range 2-8

XTerra® Manufacturing Process: Much More Than a Surface Modification

Hybrid Particle TechnologyXTerra® Columns

The vast majority of reversed-phase HPLC separations take place on silica-based stationary phases. Silica has long enjoyed such attributes as highefficiency and mechanical strength. However, silica suffers from poor peak shape for bases and a limited pH range. One way that chromatographershave attempted to overcome these limitations is by turning to polymer-based stationary phases. Polymers, however, have not enjoyed the acceptanceof silica due to poor efficiency, low mechanical strength, and unpredictable peak elution order when transferring methods from polymeric to silica-based columns.

Hybrid Particle Technology overcomes these limitations and combines the best attributes of both these materials while overcoming each material’sweaknesses. The result is a rugged material that has high mechanical strength, high efficiency, excellent peak shape for bases, and easy scale-upfrom analytical to preparative chromatography.

Pharmaceutical scientists in the areas of drug discovery, drug development, and drug isolation and purification have enthusiastically embraced theHybrid Particle Technology of XTerra® columns. This acceptance has resulted in XTerra® columns becoming the fastest selling family of HPLC columnsin the history of Waters Corporation. In addition, R&D Magazine awarded Waters a 2000 R&D 100 Award for the XTerra® family of HPLC columns.

The Efficiency of Silica with Stability of Polymers

XTerra® RP18: 4.6 x 150 mm, 5 µm, pH 10.7 Polymer Column: 4.1 x 150 mm, 10 µm, pH 10.7

Silica Separations at Polymer pH

4

0

0.1

0.2

0.3

0.4

0.5

1

3

2

4

6

5

6

54

3

2

1

10 20

AU

AU

0

0.4

0.8

1.2

10 20

1. Codeine 3. Thebaine 5. Reserpine

2. Yohimbine 4. Cocaine 6. Methadone

Conditions:

Mobile Phase A: 20 mM NH4OH, pH 10.7

Mobile Phase B: ACN

Flow Rate: 3 mL/min

Gradient: Time Profile(min) %A %B0.00 70 3025.00 40 6028.00 40 60

Injection Volume: 5 µL

Temperature: Ambient

Detection: UV @ 220 nm

Instrument: Waters 2690, 996 PDA

Time (Min) Time (Min)

XTerra® Combines the Best Properties of Silica and Polymers

Hybrid Particle Technology

Organic vs. Inorganic HPLC packings

Inorganic(Silica)

Organic(Polymer)

Advantages

• Mechanically strong• High efficiency• Predictable retention

Disadvantages

• Limited pH range• Tailing peaks for bases• Chemically unstable

• Wide pH range• No ionic interactions• Chemically stable

• Mechanically weak• Low efficiency• Unpredictable retention

Analytes:

XTerra® MS

XTerra® MS C18

and MS C8columns were designed to be compatible with Mass

Spectrometry applications and provide sharp peaks, good sensitivity, and largepeak capacities. These chemistries exhibit peak shape usually only achievablewith columns employing embedded polar group technology (see XTerra® RPcolumns). The tri-functional bonding chemistries of XTerra® MS columns deliverthe longest lifetimes over the widest pH range (pH 1-12) and provide maximumthroughput with excellent resolution and ultra-low bleed.

XTerra® RP

XTerra® RP18

and RP8

columns combine Hybrid Particle Technology with ShieldTechnology* by incorporating an embedded polar group to deliver the bestpossible peak shape. These general purpose columns allow fast method development by offering unique selectivity. Like all XTerra® columns, theshielded XTerra® RP columns exhibit excellent water wettability, even in 100%aqueous mobile phases. The combination of a greatly widened pH range forselectivity choices and the additional selectivity options of two ligands areoften the only tools necessary for successful method development.

XTerra® Phenyl

XTerra® phenyl columns offer complementary selectivity as compared tostraight-chain alkyl stationary phases, especially for compounds with aromaticrings. The combination of Hybrid Particle Technology and the XTerra® phenylchemistry results in a stationary phase with high pH stability, optimal surfacecoverage, excellent peak shape for all compounds and highly reproducibleretention times. In addition, the difunctional bonding chemistry of the shortchain phenyl ligand imparts improved low pH hydrolytic stability. This uniquecombination of substrate and ligand adds a new dimension in selectivity forseparations of complex mixtures.

Particle/Ligand Structure Effect of XTerra® Stationary Phase on Selectivity

XTerra® Chemistries

Available XTerra® Columns and Chemistries

RP8

MS C 8

RP18

MS C 18

Phenyl O Si

CH3

CH2 CH

CH3

O

O Si

O

O

O Si

CH3

CH3

O SiO

O

O Si

CHPolar Group

Polar Group

3

CH3

Sharpest peaks

Trifunctional bonding

Longest lifetimes

pH 1-12

Ideally suited for Mass Spec

RP8

MS C 8

RP18

MS C 18

Phenyl O Si

CH3

CH2 CH

CH3

O

O Si

O

O

O Si

CH3

CH3

O SiO

O

O Si

CHPolar Group

Polar Group

3

CH3

Best peak shape for basesShield technologypH 2-12Ideally suited for UV, fluorescence, electrochemical, and RI detectors

RP8

MS C 8

RP18

MS C 18

Phenyl O Si

CH3

CH2 CH

CH3

O

O Si

O

O

O Si

CH3

CH3

O SiO

O

O Si

CHPolar Group

Polar Group

3

CH3

ComplimenteryselectivityDifunctional bondingExcellent peak shapefor all compoundspH 1-12Ideally suited for Mass Spec

1

10.00 20.00 30.00

2

3

1

10.00 20.00 30.00

2

3

1

10.00 20.00 30.00 40.00 50.00

2

3

60.00

1. Quercetin2. Isorhamnetin3. Kaempferol

XTerra® MS C8

XTerra® RP8

1

10.00 20.00 30.00

2

3

1

10.00 20.00 30.00

2

3

1

10.00 20.00 30.00 40.00 50.00

2

3

60.00

1

10.00 20.00 30.00

2

3

1

10.00 20.00 30.00

2

3

1

10.00 20.00 30.00 40.00 50.00

2

3

60.00

XTerra® Phenyl

Time (Min)

Time (Min)

Time (Min)

Comments

XTer

ra®

MSXT

erra

®RP

XTer

ra®

Phen

yl

Conditions:

Columns: 4.6 x 150 mm, 5 µmMobile Phase: 52% 0.1% H

3PO

4, pH 3.0

48% MeOH (v/v)Flow Rate: 1.0 mL/minTemperature: 35 ˚CDetection: UV @ 270 nm

Waters 2690, 996 PDA

Packing Particle Shape Particle Size(s) (µm) Pore Size (Å) Carbon Load (%) End-capped

XTerra® MS C18

Spherical 2.5, 3.5, 5, 10 125 15.5 yesXTerra® MS C

8Spherical 2.5, 3.5, 5, 10 125 12.0 yes

XTerra® RP18

Spherical 3.5, 5, 10 125 15.0 yesXTerra® RP

8Spherical 3.5, 5, 10 125 13.5 yes

XTerra® Phenyl Spherical 3.5, 5 125 12.0 yes

*US Patent No. 5,374,755

XTerra® columns are available in over 600 configurations, ranging from capillary to prep.XTerra® stationary phases come in five different chemistries, each with a range of particle sizes appropriate for most applications.

XTerra® Columns

Analytes:

Ruggedness, Efficiency and Speed

The Hybrid Particle Technology of XTerra® columns results in an extremely rugged and efficient particle that is resistant to the DMSO

injections commonly performed in the drug discovery laboratory. These small XTerra® particles are then packed into short columns

which allow for faster gradients and shortened analysis times. The benefits for drug discovery scientists include high throughput,

minimized sample backups and faster library screening.

6

Drug Discovery

Speed, resolution, capacity—these attributes are crucial to the success of the drug discovery scientist. With automated

synthesizers capable of producing over a thousand potential lead compounds per day, sample backups are common in the

chromatography laboratory. Eliminate sample backups while characterizing, analyzing and purifying combinatorial libraries

faster than ever before by running ultrafast gradients on XTerra® MS columns.

To maximize sample throughput, analytical run times must be shortened while still maintaining high peak capacity.

The combination of short XTerra® columns containing 2.5 µm particles, together with high flow rates and fast gradients

creates a breakthrough in speed, resolution and capacity—without compromise. In addition, XTerra® columns can be

operated at temperatures up to 80 ˚C, thereby lowering system backpressure.

Van Deemter Curves for XTerra® MS C18

Columns

Speed with Resolution

Drug Discovery

Increasing Flow Rates and Higher Peak Capacity

0.12

0

50

100

150

200

0.16 0.23 0.33 0.47 0.66 0.93 1.32 1.86 2.63 3.72 5.26 7.45 10.53

16.0

8.0

4.0

2.0

1.0

32.0

0

50

100

150

200

0.07 0.10 0.14 0.20 0.28 0.39 0.56 0.79 1.12 1.58 2.23 3.16 4.478.936.32

16.0

8.0

4.0

2.0

1.0

32.0

16.0

8.0

4.0

2.0

1.0

32.0

0.05 0.07 0.09 0.13 0.19 0.26 0.37 0.53 0.74 1.05 1.49 2.11 2.985.96 8.42

4.21

0

50

100

150

200

Flow rateFlow rate

Flow ratetg tg tg

Peak

Capa

city

40

35

30

25

20

15

10

0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.05

As particle size decreases, improved peak capacity and resolution is obtained at high speed. These parameters can besuccessfully optimized to obtain faster separations while retaining maximum resolution.

4.6 x 50 mm 5 µm 4.6 x 30 mm 3.5 µm 4.6 x 20 mm 2.5 µm

5 µm

2.5 µm

Linear Velocity (mm/sec)

Plate

Heigh

t (µm

)

Short Gradient (tg) with Higher Peak Capacity

Smaller Plate Height=Higher Efficiency=Increased Peak Capacity

Smaller Particles ProvideHigher Efficiency atFaster Flow Rates

Faster flow rates and shorter columns allow for shorter gradient run times—without compromisingpeak capacities. For mass spectrometry compatible flow rates, these same advantages are realizedfor smaller diameter columns as well.

Shorter Columns, Higher Flow Rates, and Higher Peak Capacities

Smaller Particles and Shorter Columns Result in Faster Runs

www.waters.com/xterra

Automated LC/UV/MS is the technique of choice for the characterization of combinatorial libraries produced by high

output automated synthesizers. XTerra® MS columns were created for LC/MS with ultra-low MS bleed from pH 1-12.

XTerra® columns provide the speed and resolution necessary to fully utilize the selectivity, sensitivity and structural

characterization capabilities of today’s powerful Mass Spectrometers.

In order to achieve the high sensitivities and low limits of detection required for drug metabolism studies, a total

analysis solution is required. Waters provides this complete answer by combining Oasis® sample preparation products,

XTerra® columns, Alliance® LC systems, and Micromass mass spectrometers to produce the best possible combination of

speed, resolution and sensitivity for your LC/MS analyses.

Columns Designed with Mass Spectrometry (MS) in Mind

LC/MS Separation at Low, Medium, and High pH Low Level Drug Determination by SPE/LC/MS

8

High Sensitivity LC/MS Analyses

35

35

3 2

41

2

41

4

2

1

pH=10.5

pH=5

pH=2.7

0 3 0 3

0 3

0 3

0 3

0 3

TIC ES– TIC ES+

Using a single XTerra® column, both resolution and MS signal can be optimized for acids, bases and neutrals while maintainingunsurpassed peak shape and peak capacity.

Using an Oasis® MCX extraction method with a 10 mg 96-well extraction plate, EDTA rat plasma wasextracted and analyzed for the histamine H2-receptorantagonist ranitidine using an XTerra® MS C

18column

on an Alliance® LC/MS System.

Conditions:

Column: XTerra® MS C18

2.1 x 30 mm, 3.5 µm

Mobile Phase A: 0.1% HCOOH in 3% ACN (v/v)Mobile Phase B: 0.1% HCOOH in 100% ACN

Mobile Phase A: 10 mM CH3COONH

4in 3% ACN (v/v)

Mobile Phase B: 10 mM CH3COONH

4in ACN

Mobile Phase A: 0.1% NH4OH in 3% ACN (v/v)

Mobile Phase B: 0.1% NH4OH in ACN

Gradient: Time Profile

(min) %A %B0.00 95 52.00 5 953.00 5 95

Flow Rate: 1.5 mL/min

Splitter ca. 180 µL/min (split 10:1)



MS Conditions

Ion Source: Electrospray positiveElectrospray negative

SourceTemperature: 150 ˚C

DesolvationTemperature: 350 ˚C

Instrument: Alliance® HT 2795 w/ ZQMass Detector

100 200 3000

100

m/z

%

175.82Ranitidine

143.86123.85

223.94 269.95315.08

SO H

NHN

CH3

CHNO2

NH3C

H3C

0

100

1.801.40 2.201.000.600.20

%

0

100

%

Analytes: Conc. (µg/mL DMSO)

1: Lidocaine 0.294

2: Prednisolone 1.710

3: Naproxen 0.206

4: Amitriptyline 0.163

5: Ibuprofen 0.784Conditions:


2.1 x 30 mm, 3.5 µmMobile Phase: 30% 0.1 M HCOONH

4

70% ACN (v/v)Flow Rate: 200 µL/minInjection Volume: 15 µLTemperature: AmbientMS ConditionsIon Source: Electrospray positiveSource Temperature: 150 ˚CDesolvationTemperature: 350 ˚CInstrument: Alliance® HT 2795

w/ ZQ Mass Detector

Internal Standard spike 1.0 ng/mL

MRM of 2 channels ES+

271>140

9.35e5

Plasma spike 1.0 ng/mLranitidine 1161 Sm (Mn, 2 x 4) MRM of 2 channels ES+

315>175.9

1.66e4

Daughters of 315ES+cid 15 2.99e8S3 1 (1.005)

CID Mass Spectra

pH 2.7

pH 5

pH 10.5

Time (Min) Time (Min)

Gradient (tg) = 2 min

Relat

ive A

bund

ance

(%)

Time (Min)

Open access walk-up LC systems run fast, generic gradients and are often the starting point for testing samples that contain

a wide range of chemical compounds. XTerra® IS ™ columns are ideally suited for these high throughput systems. XTerra®

IS ™ columns combine a rugged and efficient particle with advanced column hardware and packing techniques to provide

faster run times, increased sample throughput and shorter product development time.

The fast and efficient chromatography realized with XTerra® columns can be directly and easily scaled to preparative

applications. This allows new drug candidates to be taken directly from the lead generation to the lead optimization stage

of drug discovery. The ability to operate at high pH provides excellent peak shapes for bases and increased mass loading

(up to 60x) as compared to conventional silica-based materials.

Intelligent Speed (IS ™) Columns for Fast Generic Gradients

Complex Test Mix Run on XTerra® MS C18

IS ™ Column

Direct Scale-up CapabilityDrug Discovery

Accurate Discovery Scale-up

-0.02

0.00

0.02

0.04

0.06

0.08

0.10

0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00

1

2

3

4

7

9

10

658

V0

AU

A wide range of compounds was baseline separated in less than 3.5 minutes. This separation is representative of LC column testingin major pharmaceutical laboratories around the world.

With XTerra® columns, ”redevelopment” time is minimized and separations can easily be scaled up from analytical to prep.

Analytes:

1. 8-Bromoguanosine

2. Acetanilide

3. Triamcinolone

4. Hydrocortisone

5. 2-Amino-7-chloro-5-oxo-5H[1]benzopyrano [2,3-b]pyridine- 3-carbonitrile

6. 6 a-Methyl-17a-hydroxyprogesterone

7. 3-Aminofluoranthene

8. 2-Bromofluorene

9. Perylene

10. Naphtho(2,3-a)pyrene

Time (Min)

Conditions:

Column: XTerra® MS C18, 2.1 x 20 mm IS TM, 3.5 µm

Mobile Phase A: 0.1% HCOOHMobile Phase B: 0.1% HCOOH in ACNFlow Rate: 0.6 mL/minGradient: Time Profile

(min) %A %B0.0 100 0 4.0 0 100

Injection Volume: 5 µLSample Concentration: 20 µg/mLTemperature: 30 ˚CDetection: UV @ 254 nmInstrument: Alliance® 2795 with 996 PDA

- 1

100

%

1 2

34

2.00 4.00 6.00 8.00-1

100

%

1 2

34DMSO

DMSO

Time (Min)

Conditions:

Mobile Phase A: 10 mM NH4HCO

3, pH 10

Mobile Phase B: ACN/100 mM NH4HCO

3, pH 10 (90/10)

Sample Concentration: 15 mg/mL each in DMSOTemperature: AmbientDetection: UV @ 210 nmInstrument: Waters AutoPurification® System

Analytes:

1. Ethyl-4-hydroxybenzoate2. Diphenhydramine3. Dibenzofuran4. N-phenylcarbazole

Flow Rate: 1.05 mL/minGradient: Time Profile

(min) %A %B0.00 95 50.19 95 54.19 0 1007.19 0 1007.20 95 512.0 95 5


Flow Rate: 18.0 mL/minGradient: Time Profile

(min) %A %B0.00 95 51.00 95 55.00 0 1008.00 0 1008.01 95 512.0 95 5



4.6 x 50 mm, 5 µmMass Load: 3.5 mg


Prep OBD™ 19 x 50 mm, 5 µm

Mass Load: 60.0 mg


Harness the Power of pH

XTerra® columns allow the method development scientist to operate under whatever conditions are necessary for optimal selectivity.

With a pH operating range that is twice as wide as silica, XTerra® columns enable the development scientist to harness one of the

most powerful tools for optimizing retention times during method development— pH. This results in faster and easier development

of more robust and reproducible chromatographic separations.

10

Method Development

One of the greatest challenges facing the method development scientist is creating a robust separation in the most time efficient

manner possible. Tools available to the separations scientist that influence elution order (selectivity) include solvent type,

pH column chemistry and/or temperature. The unique Hybrid Particle Technology of XTerra® columns allows the greatest

flexibility for selecting whatever chromatographic conditions are necessary for optimal selectivity and separation.

One of the most powerful tools for manipulating the selectivity for ionizable compounds is pH. Acidic compounds have

increased retention at pH values below their pKa

and basic compounds exhibit longer retention at pH values above their

pKa. Since many pharmaceutically active compounds are ionizable, a column with a wider usable pH range allows for

greater retention time manipulation during method development. XTerra® columns have a usable pH range (pH 1-12) that

is twice as wide as silica based columns, thereby making method development twice as easy and twice as fast.

Optimize Selectivity for Ionizable Compounds Develop Robust Separations for Basic Compounds at High pH

Increase Retention of Basic Compounds at Higher pH

N

0

1

2

3

4

5

6

7

8

9

10

11

12

13

14

0 1 2 3 4 5 6 7 8 9 10 11 12

0 1 2 3

pH

pH 10

pH 5

pH 2

B

B

A,B

A

A

N

N

0 1 2 3

0 1 2 3

N CH

N

H3

CH3

CH3

pH

0 1 2 3 0 1 2 3

0 1 2 3 4 5 6 7 8 9 10 11 120

10

20

30

40

The wider usable pH range of XTerra® columns is a powerful tool for changing the selectivities of ionizable analytes. For the first time, XTerra® columns allow the development scientist to utilize the full power of pH as a methoddevelopment tool.

• Increasing retention• Good peak shape• Need critical control ofpH for chromatographicreproducibility

• Good peak shape• Poor retention

• Best retention• Good column lifetimes• Good peak shape• Improved chromatographic

reproducibility

Capa

city

Facto

r (k)

Capa

city

Facto

r (k)

Time (Min)

Neutral (N)

Acid (A)

Base (B)

Amitriptyline

Nortriptyline

Co-elution at pH 3

Time (Min)

AmitriptylineNortriptyline

Nortriptyline

Amitriptyline

{ }

Time (Min)

Separation of very similar bases at pH 10

Method Development

Maximize Selectivity with the Wider pH Range


The quality of peak shapes for basic analytes is dependent upon the concentration, type and activity of residual silanols

that are present after bonding. It is difficult to reduce the number of silanols on silica by more than 50%, even after ligand

bonding and endcapping. For XTerra® columns, one third of the surface silanol groups are replaced with methyl groups

prior to ligand bonding and endcapping, resulting in the highest, most homogeneous coverage of any reversed phase material.

This 33% reduction in silanol concentration delivers the sharpest and most symmetrical peaks for basic analytes regardless of

mobile phase.

The exceptional peak shape achieved on XTerra® columns extends across a pH range that was not previously achievable

with silica-based columns. With a single XTerra® column, superior peak shapes can be realized for acidic, neutral and

basic compounds. The result is a more robust separation for compounds in their neutral form—acidic compounds below

their pKaand basic compounds above their pK

a—since pH control becomes less critical.

Use pH to Improve Peak Shape and Increase Retention

Excellent Resolution and Peak Shape at High pH

12

Superior Peak Shape for Any Compound in Any Mobile Phase

1.00

1.10

1.20

1.30

1.40

1.50

1.00

1.10

1.20

1.30

1.40

1.50

pH 3.0 pH 7.0 pH 10.0

The wider pH range of XTerra® columns allows greater selectivity choices while improving peak shapeand resolution.

Regardless of mobile phase composition or analyte, XTerra® columns provide the most flexibility in developing fast and robust separations.

Time (Min)

USP

Tailin

g Fa

ctor

Acetonitrile(ACN)

USP

Tailin

g Fa

ctor

Methanol(MeOH)

Salicyclicacid

Nicotine p-Toluamide Salicyclicacid

Nicotine p-Toluamide

10 mM NH4HCO

3

25% ACNpH 7.0

10 mM HCOONH4

25% MeOHpH 3.0

Salicyclicacid


10 mM NH4HCO

3

15% ACNpH 10.0

Salicyclicacid

Acidic Compound Neutral Compound Basic Compound


10 mM HCOONH4

35% MeOHpH 3.0

Salicyclicacid


10 mM NH4HCO

3

27% MeOHpH 7.0

Salicyclicacid


10 mM NH4HCO

3

25% MeOHpH 10.0

Improved Peak Shape for XTerra® at Any pH

Conditions:Column: XTerra® RP

18, 4.6 x 50 mm, 3.5 µm

Mobile Phase A: H2O

Mobile Phase B: MeOHMobile Phase C: 100 mM NH

4HCO

3, pH 9.0

Flow rate: 2.0 mL/minGradient: Time Profile

(min) %A %B %C0.0 90 0 102.0 30 60 1010.0 16 74 1012.0 90 0 1015.0 90 0 10

Injection Volume: 20 µL Temperature: 30 ˚CDetection: UV @ 254 nmInstrument: Alliance® 2695, 2996 PDA

0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00

1

2 3 4

56

7

Analytes:1. Trimethoprim2. Nordoxepin3. Nortriptyline4. Doxepin5. Imipramine6. Amitriptyline7. Trimipramine

Another powerful method development tool is column stationary phase chemistry. The choice of XTerra® columns, available

in five different ligands, can have a marked effect on selectivity. These complementary column chemistries are part of an

overall method development routine that also includes pH, organic modifier and temperature. These chemistries, along

with a wider pH range, superior peak shape and excellent lot-to-lot reproducibility make XTerra® the only columns necessary

to develop robust HPLC methods.

XTerra® columns are part of a streamlined method development routine that includes: two pH levels (e.g., pH 3.0 and

pH 10.0), three XTerra® columns (e.g., XTerra® MS C18, RP

18, and Phenyl), and two organic modifiers (ACN and MeOH).

Using a generic gradient and MS for rapid peak elution and identification, 12 experiments (2x3x2) provide the exploratory

work necessary to find the most promising separation. After this initial exploratory work, fine-tuning can be performed

using solvent selectivity, pH or temperature.

Use Column Chemistries to Change Selectivity

Effect of XTerra® Column Chemistry on Selectivity and Retention

Streamlined Method DevelopmentMethod Development

Easy and Fast Method Development

21

5 10 15 20 25

4

5

6

3

2

1

4

5

6

3

21

4

5

6

5 10 15 20 25

5 10 15 20 25

O Si

CH 3

CH 2 CH

CH 3

O

O Si

O

O

O Si

CH 3

CH 3

3

The column stationary phase chemistries of XTerra® columns are key components in an overall method development plan.

Conditions:Columns: 4.6 x 150 mm, 5 µm

Mobile Phase A: H2O

Mobile Phase B: MeOHMobile Phase C: 50mM HCOOH,

pH 2.45

Gradient:Time Profile(min) %A %B %C0.00 40 50 1020.00 25 65 1035.00 25 65 10



Temperature: 30 ˚C

Detection: UV @ 254nm


Analytes: 1. Suprofen2. Tolmetin3. Naproxen4. Fenoprofen5. Ibuprofen6. Diclofenac

XTerra® Phenyl

XTerra® RP8

XTerra® MS C8

This twelve experiment gradient method development routine can easily be automated and is often all that is necessary todevelop separations of complex samples.

MeOH, ACN, MeOH, ACN,low pH low pH high pH high pH




Time (Min)

Time (Min)

Time (Min)

XTerra® RP18

XTerra® RP18 Þ XTerra® RP

18 Þ XTerra® RP18 Þ XTerra® RP

18

XTerra® MS C18

XTerra® MS C18 Þ XTerra® MS C

18 Þ XTerra® MS C18 Þ XTerra® MS C

18

XTerra® Phenyl XTerra® Phenyl Þ XTerra® Phenyl Þ XTerra® Phenyl Þ XTerra® Phenyl


Sample Preparation:

SPE: Oasis® HLB µElution PlateCondition: 200 µL MeOHEquilibrate: 200 µL H

2O

Load: 150 µL Spiked rat plasma with 2% H3PO

4,

diluted with 1:1 H2O

Wash: 200 µL 5% MeOH in H2O

Elute: 50 µL MeOHDilute: 100 µL H

2O

Because pharmaceutical companies are being pressed to bring products to market sooner, method development scientists are

being asked to develop shorter and faster separations. The challenge is to do this without sacrificing analyte resolution or

method robustness. Waters has made this possible by producing XTerra® IS™ columns which combine state-of-the-art column

packing techniques and hardware to produce efficient, stable and reproducible 20 mm length analytical columns.

Waters set the standard for reproducibility with the Symmetry® family of columns in 1994. This high level of quality continues

with XTerra® columns. As with all modern Waters stationary phases, reproducibility, excellent peak shape and long column

lifetimes are assured since all Waters columns are manufactured in cGMP, ISO 9002 certified facilities. The method development

scientist can be confident in, not only the results but also in the ability to transfer the method to QC.

Develop Shorter and Faster Methods Using Intelligent Speed (IS™) Columns

Develop Faster Methods

14

Excellent Batch-to-Batch Reproducibility

MRM485.2 > 165.1

4.83e6

4.24

MRM 278 > 233.1

1.28e6

4.75

MRM278 > 205.1

2.50e6

2.96

MRM267 > 190.1

3.18e5

2.60

MRM260 > 183

6.26e5

3.92

MRM195 > 138

3.64e5

2.12

1.00 2.00 3.00 4.00 5.00 6.00

MRM of 6 Channels ES+ TIC

4.86e6

5

3

1 2 4

6

0.00

LC Conditions:

Column: XTerra® MS C18, 2.1 x 20 mm IS™, 3.5 µm

Mobile Phase A: 10 mM NH4HCO

3, pH 10

Mobile Phase B: MeOHFlow Rate: 0.4 mL/minGradient: Time Profile

(min) %A %B0.0 100 05.0 5 95

Injection Volume: 20 µLSample concentration: 5 µg/mLTemperature: AmbientDetection: MS

Instrument: Waters 2777 Sample Manager, Waters 1525 Binary HPLC Pump and Waters Micromass® Quattro Ultima™ MS

MS Conditions:Quattro Ultima™

ES+ MRMCone (V) 5.0Capillary (kV): 3.5 Source (˚C): 150Desolvation (˚C): 400Cone gas flow (L/hr): 50 Desolvation gas flow (L/hr): 550 LM resolution 1&2: 13.5HM resolution 1&2: 13.5Ion Energy 1: 0.4Ion Energy 2: 0.8Multiplier (V): 650

2003

2002

2001

2000

0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00

2004

Time (Min)

Year

Reproducible and Predictable Results Year After Year

%RSD 1.27 0.90 1.46 1.11 0.7 0.84

Overlay of QC batch test chromatograms taken from five batches of XTerra® RP18, 5µm stationary phase

material. XTerra® columns produce reproducible and predictable results year after year.

Analytes:1. Caffeine2. Practolol3. N-acetyl procainamide4. Propranolol 5. Methoxyverapamil 6. Amitriptyline

Time (Min)

In addition to a wider pH range and superior peak shape, another benefit of Hybrid Particle Technology for method development

is extended column lifetime. This is due to the ruggedness of the XTerra® particle. The molecular structure of the XTerra®

particle imparts greater resistance to dissolution at high pH as compared to traditional silica-based particles. XTerra®

columns exhibit the pH resistance of a polymer and the performance of silica.

The Hybrid Particle Technology of XTerra® columns provides longer column lifetimes across a much wider pH range than silica.

Even the “newer” silica-based columns that are reported to have longer lifetimes when running at high pH, require several

different column chemistries to span the pH range of one XTerra® column. When running separations, using XTerra® columns

over extended periods of time at high pH, no loss in retention time or deterioration of peak shapes is observed.

Rugged Particles Mean Longer Column Lifetime

Improved Robustness of the XTerra® Particle

Bonded Silica Particle Bonded XTerra® Particle

Conditions:Column: XTerra® RP

184.6 x 150 mm, 5 µm

with 3.9 x 20 mm XTerra® RP18

guard columnMobile Phase: 50% 50 mM Pyrrolidine, pH 11.5

50% ACN (v/v)

Flow Rate: 1.0 mL/minute


Temperature: 30 ˚C



Day 1 Day 45

1. Methamphetamine 1.2 1.22. Propranolol 1.3 1.33. Nortriptyline 1.1 1.1

• Complete dissolution of silica• Catastrophic column failure• Short lifetimes

• Slow rate of surface dissolution• Incorporated methyl groups

uncovered slow rates of dissolution• Longer column lifetimes

OH- OH- OH- OH- OH-

Si

O

O O Si

O

O Si

O

O Si

O

O Si

O

O Si

O

OHOH

OSi

Si

O

O O

O O Si

O

O

Si

O

Si

O

Si

O

O Si

O

O O O O O O O

OH OH OH

SiO O Si O Si O Si O Si O Si OSiO O Si O Si

Surface

Core

Si

O

O Si

O

Si

Si Si Si Si Si Si

Si

O

O

O

O

Si

O

Si

O

Si

O

Si

O

O O O OO O

Si O Si Si

Si O Si

OH

OH

OH

OH

OH

OH

OH

OH

OH

OH OH OH

OH

OHOH

OH

Si(OH)4 Si(OH)4 Si(OH)4

Surface

Core

Surface

Si

O

OH

OH

O Si

O

Si

O

O Si

O

O Si

O

OSi

Si

O

O

O O Si

O

O

Si

O

Si

O

O O O O O

Si O O Si O Si O Si O Si O Si OSi O O Si O Si

Core

OH

OHOH

OH

Si(OH)4Si(OH)4

CH3

CH3

CH3

CH3

CH3

CH3CH3

CH3 CH3

OH- OH-

Si

O

O O Si

O

O Si

O

OH

O Si

O

O Si

O

O Si

O

OSi

Si

O

O

O O Si

O

O

Si

O

Si

O

O Si

O

O O O O O

OH


CH3

CH3

CH3

CH3

CH3

CH3

CH3

Surface

Core

OH- OH- OH- OH- OH-

Si

O

O O Si

O

O Si

O

O Si

O

O Si

O

O Si

O

OHOH

OSi

Si

O

O O

O O Si

O

O

Si

O

Si

O

Si

O

O Si

O

O O O O O O O

OH OH OH


Surface

Core

Si

O

O Si

O

Si

Si Si Si Si Si Si

Si

O

O

O

O

Si

O

Si

O

Si

O

Si

O

O O O OO O

Si O Si Si

SiO Si

OH

OH

OH

OH

OH

OH

OH

OH

OH

OH OH OH

OH

OHOH

OH

Si(OH)4 Si(OH)4 Si(OH)4

Surface

Core

Surface

Si

O

OH

OH

O Si

O

Si

O

O Si

O

O Si

O

OSi

Si

O

O

O O Si

O

O

Si

O

Si

O

O O O O O

Si O O Si O Si O Si O Si O Si OSi O O Si O Si

Core

OH

OHOH

OH

Si(OH)4Si(OH)4

CH3

CH3

CH3

CH3

CH3

CH3CH3

CH3 CH3

OH- OH-

Si

O

O O Si

O

O Si

O

OH

O Si

O

O Si

O

O Si

O

OSi

Si

O

O

O O Si

O

O

Si

O

Si

O

O Si

O

O O O O O

OH


CH3

CH3

CH3

CH3

CH3

CH3

CH3

Surface

Core

5 10

1

2

3

XTerra® columns exhibit superior stability at high pH, separating basic compounds with no deterioration of plate count orpeak symmetry.

In the XTerra® particle, the presence of the methyl silox-ane bond throughout the particle results in increasedresistance to dissolution in high pH mobile phases.

At high pH, the hydroxyl anion in the mobile phase attacksthe silica surface, thereby causing dissolution of the silica.This is accelerated as more silanol sites become exposed.

Time (Min)

Initial Injection

After 45 Days

USP Tailing Factor

Method Development

Longer Column Lifetimes at High pH


Bridging the Performance Gap from Analytical to Prep

Introducing the new XTerra® Prep OBD™ columns from Waters that deliver analytical performance in preparative dimensions with maximum

column stability the result of patent-pending Optimum packed Bed Density (OBD™) design. Combining OBD™ design with the unique

chromatographic properties of XTerra® Hybrid Particle Technology provides a range of high performance preparative columns with

unprecedented flexibility, both through the range of analytes— basic, acidic and polar—and the wide operating range of mobile

phases necessary for successful, predictable preparative scale-up.

16

Isolation/Purification

The purification process invariably requires HPLC injections of large volumes of sparingly soluble material dissolved in strongsample solvents. This combination has been recognized to be one of the primary contributors to early preparative columnfailure. The challenge for the column supplier is to reproducibly manufacture preparative columns with the same performanceand stability as the equivalent analytical column.

The proprietary Optimum Bed Density OBD™ procedure yields preparative columns with the same packed bed densities astheir analytical counterpart resulting in durable bed stability, better efficiency and higher loadability.

Consistency of column lifetime is a key consideration not only for high throughput applications, but also in the planningof the annual budget requirements of a purification laboratory.

Interaction between basic analytes and ionizable silanols on silica surfaces results in poor peak shape. Therefore, separationof basic compounds is often performed at low pH to suppress silanol ionization, thereby reduce peak tailing. However, inthis mode, basic analytes are protonated and are not retained well by reversed-phase sorbents.

However, XTerra® Prep columns with Hybrid Particle Technology—unlike traditional silica columns—can be used routinely athigh pH so that basic compounds can be separated in their neutral form. This results in a tremendous improvement, not only inpeak shape, but also resolution and loadability. Moving from an isocratic to a gradient separation mode further increases capacity.

Introducing Optimum Bed Density (OBD™) Design Increase Mass Capacity and Resolution for Drug Development

Consistent Column-to-Column Performance

Isolation/Purif ication

Before and After QC Test Comparisons on XTerra® Prep OBD ™ Columns

Plates USP Tail Plates USP Tail

1 4,278 1.14 3,927 1.17 -8.22 4,430 1.05 4,129 1.07 -6.83 3,943 1.02 4,054 1.08 2.84 4,093 1.03 3,945 1.13 -3.6

Average 4,186 1.06 4,014 1.11 -4.0

Post 1000 Injections % Change in Efficiency

New ColumnsColumn

Conditions:Columns: Four XTerra® Prep MS C

18 OBD™

19 x 50 mm, 5 µm

Mobile Phase A: 1.0% HCOOH

Mobile Phase B: 1.0% HCOOH in ACN


Gradient: Time Profile(min) %A %B Analytes:0.0 95 5 1. Tylosin4.5 25 75 2. Sulfathiazole5.0 25 75 3. Ketoprofen

Injection Volume: 400 µL DMSO



Instrument: Waters Purification Factory

Injection 14

Injection 955

2

1

3

2Day 10Column 1

Day 1Column 1

1

3

1 2

10

%

-1

10

%

0

3 4 5 6

-6

100

% pH 10Load 6.4 mg

2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00-1

100

%pH 10

Load 80 mg

-0

100

%

2

1

pH 2.3Load 6.4 mg

Conditions:Column: XTerra® Prep MS C

18 OBD™

19 x 100 mm, 5 µm

Mobile Phase A: 0.1% TFA pH 2.3

Mobile Phase B: 0.1% TFA in ACN

Mobile Phase A: 10 mm NH4HCO

3pH 10

Mobile Phase B: 100 mm NH4CO

3/ACN (10/90)

Gradient: Time Profile Analytes:(min) %A %B 1. Miconazole0 95 5 2. Econazole1.0 95 511.0 10 9016.0 10 90

Injection Volume: 1000 µL pH 2.3

4000 µL pH 10.0



Instrument: Waters Autopurification® System

XTerra® columns provide superior stability at high pH, separating basic compounds with enhanced resolution and loadability.

Low vs High pH Loading

XTerra® Prep OBD™ exhibit unmatched column-to-column stability

www.waters.com/prepcolumn

Time (Min)

Time (Min)

The key to successful purification is obtaining a good analytical separation and the ability to scale-up directly without modifying the mobile or stationary phase.

The isolation and purification of critical compound pairs is a major challenge to purification scientists. Often a successful analytical separation will not scale up directly due to the reduced performance of the preparative column.

The OBD™ design ensures equivalent chromatographic performance from analytical to preparative dimensions, eliminating the need for any subsequent method redevelopment.

Predictable sample loadability allows efficient purification of the required mass for preclinical drug metabolism studies.

Accurate Scalability to Larger Column Dimensions

Scalability for Drug Discovery / Lead Optimization

18

31

2

3 4 5 6

3 4 5 6

31 2

31 2

31

2

3 4 5 6

3 4 5 6

3 4 5 6

31 2

31 2

3 4 5 6

3 4 5 6

3 4 5 6

31 2

31 2

Conditions:Mobile Phase A: 1% HCOOH in H

2O

Mobile Phase B: 1% HCOOH in ACN

Flow Rate: 1.8 mL/min (4.6 x 50 mm) 31.0 mL/min (19 x 50 mm)* 77.0 mL/min (30 x 50 mm)**

Gradient:

Time (min) %A %B Curve0.00 90 10 111.0 90 10 65.0 37 63 65.5 10 90 66.5 10 90 67.0 90 10 610.0 90 10 6



Instrument: Waters Autopurification® System

Gradient Adjustment: *Add 0.35 min to each time point on gradient table.

**Add 0.5 min to each time point on gradient table.


Column: XTerra® Prep MS C18

OBD™ Column: XTerra® Prep MS C18

OBD™

4.6 x 50 mm, 5 µm 19 x 50 mm, 5 µm 30 x 50 mm, 5 µm

Load: 3 mg Load: 51 mg Load: 128 mg

Analytes: 1. Oxacillin

2. Cloxacillin

3. Dicloxacillin

Time (Min) Time (Min) Time (Min)

Excellent scalability of acidic compounds at low pH across three dimensions.

Pictured here is the Waters FractionLynx™ MS with a2767 Sample Manager for inject/collect/re-inject,2525 Binary Gradient Module for high pressure mixing,Column Fluidics Organizer for software-controlled valving,fluidics, and column management, 2996 PDA and ZQ™

Mass Detector.

XTerra® Prep columns deliver the speed you need for high throughput lead generation—speed that enables rapid analysis and purification of thousands of samples. Now you can screen and

purify your libraries twice as fast, compared to traditional silica-based columns.

XTerra® packings, engineered specifically for preparative chromatography, allow you to operate routinely in a wider pH range (1-12). Choosing an optimum pH enables maximum column loading

(low pH for acidic compounds or high pH for basic compounds).

Hybrid Particle Technology combined with Optimum Bed Density™ always assures the best peak shapes and longest column lifetimes.

Screen and Purify Libraries in Half the Time

Optimization of High Throughput Applications

2 4 6 8 10

31

2

2 4 6 8 10

31

2

0

0

3

2 4 6 8 10

31

2

0


18 OBD™

19 x 50 mm, 5 µm

Mobile Phase A: 10mM NH4HCO

3, pH 10

Mobile Phase B: ACN

Flow Rate: 20 mL/min



Instrument: FractionLynx™ MS


18 OBD™

19 x 30 mm, 5 µm


3, pH 10

Mobile Phase B: ACN





Analytes: Conc. (mg/mL DMSO)

1: Diphenhydramine 20

2: Oxybutynin 20

3: Terfenadine 20

Fast throughput purification at high pH for basic compounds shows excellent peak shape andresolution at high loading conditions.

The larger capacity obtained at high pH enables the use of shorter columns to double purificationthroughput without compromising purity.

2 4 6 8 10

3

1

2

0


18 OBD™

19 x 30 mm, 5 µm


3, pH 10.0

Mobile Phase B: ACN





Higher throughput can be achieved by increasing the flow rate to take advantage of thereduced backpressure of this shorter column.

• Peak widths (volumes) halved• Concentration of fractions doubled • Sensitivity increased

Time (Min) Time (Min) Time (Min)

Isolation/Purif ication

www.waters.com/prepcolumn

The New Standard in Synthetic Oligonucleotide Analysis and Purification

Use of XTerra® hybrid-particle technology provides significant advantages over current methods used to analyze or purify synthetic

oligonucleotides. Compared to gel electrophoresis or other HPLC techniques, the XTerra® reversed-phase, ion-pairing HPLC method

yields superior component resolution and product recovery for either analytical or semi-preparative applications. XTerra® hybrid particles

are also available in Waters new NanoEase™ 75, 100, and 150 µm nano columns and 300 µm capillary columns for LC/MS applications.

20

Life Sciences

The successful purification of a long-chain synthetic oligonucleotide product containing substantial amounts of failure

sequences can be challenging. A novel method has been developed for the purification of such sequences using reversed-

phase high performance liquid chromatography (RP-HPLC) with an ion-pairing (IP) mobile phase. Up to 0.25 µmole of

synthetic DMT-off oligonucleotide can be purified in a single injection with this method on a 4.6 x 50 mm XTerra® column.

In addition, the isolated oligonucleotide requires no post-purification desalting or detritylation preparation prior to use.

The high coupling efficiency of DNA/RNA synthesis methods can produce high quality product provided that the automated

synthesizers are properly functioning. While “sub-optimally functioning” systems can yield acceptable material for some applications

(e.g., PCR primers), only high purity oligonucleotides (e.g., >98% pure) can be used for some diagnostic and therapeutic

applications. Use of XTerra® hybrid-particles contained in Waters Intelligent Speed (IS ™) columns is well suited for the fast, IP-RP-

HPC analysis of synthetic oligonucleotides and RNAi.

HPLC Purification of Synthetic Oligonucleotides

High Mass Load Purification for 25 nt Oligonucleotide

Life Sciences

Separation of Synthetic Oligonucleotides on XTerra® Intelligent Speed (IS™) Columns

AU

0.00

0.50

1.00

1.50

2.00

2.50

3.00

3.50

2 4 6 8 10 12

290 nm

260 nm

AU

0.00

0.02

0.04

0.06

0.08

0.10

42 6 8 10 12

UV25

4nm

20mer G

20mer C

20mer A

20mer T

N-1

N-1

N-1

N-9 N-3 N-2 N-1

0 1 2 3 4

ConditionsColumn: XTerra® MS C

18, 2.5 µm

4.6 x 50 mmMobile Phase A: 5% ACN in 0.1M TEAA, pH 7.0Mobile Phase B: 15% ACN in 0.1M TEAA, pH 7.0

Gradient: Time Profile(min) %A %B0.00 80 2015.00 42.5 57.5

Flow Rate: 1.0 ml/min

Temperature: 60 ˚C

Detection: UV @ 260 and 290 nm

HPLC System: Waters Alliance® System with Waters 2695 PDA

Conditions:Column: XTerra® MS C

18, 2.5 µm,

4.6 x 20 mm IS™ ColumnMobile phase A: 5 % MeOH in TEA/HFIP (16.3 mM/

400 mM), pH 7.9Mobile phase B: 30 % MeOH in TEA/HFIP (16.3 mM/

400 mM), pH 7.9Buffer preparation: Dissolve 41.5 mL of HFIP in ~ 950 mL

of water. While mixing vigorously, add2.3 mL of TEA. Adjust final volume to 1 L with water. The pH of the solutionshould be about 7.9

Flow rate: 1.0 mL/minuteGradient: 0—60 % B in 4.25 min.; gradient

profile 4 (concave)Injection volume: 2 µl (dissolved in mobile phase A).

200 pmole total mass loadTemperature: 60 ˚CDetection: Waters 2487 Dual Wavelength

Absorbance Detector; 254 nmHPLC System: Waters Alliance® HT Separations

Module with Waters 2487 Dual Wavelength Absorbance Detector

Separation was performed on a 4.6 x 20 mm XTerra® MS C18, 2.5 µm IS™

column. Mobile phases were comprised of 1,1,1,3,3,3-hexafluoroisopropanol(HFIP) and triethylamine (TEA) with a concave methanol (MeOH) gradient.Since XTerra® columns are packed with hybrid particles, they can be operatedat the elevated pH and temperature levels needed for DNA separation (pH7—9; 60 ˚C). The short column length (20 mm) allows for separation timesunder 5 minutes. Figure 1 shows the IP-RP-HPLC separation of four differenthomooligonucleotides (dG

20, dC

20, dA

20, and dT

20). Baseline separation of

closely eluting impurities (i.e. N—1, 2, 3, etc.) from the target oligonu-cleotide was routinely achieved.

An example of a 25 nt oligonucleotide purified using an XTerra®

column. The dashed lines indicate the start and stop of the collection.The chromatogram shows monitoring at two separate wavelengths.260 nm is the typical wavelength used to detect DNA. Since thedetector is saturated with 0.5 mMole mass load, the less sensitive290 nm detection wavelength was used for visual confirmationof the oligonucleotide separation from n-1 failure products.

StartCollection

StopCollection

Time (Min)

97% Pure

Time (Min)

HPLC Analysis of Synthetic Oligonucleotides

www.waters.com/lifescience

Time (Min)

XTerra® Capillary and Narrowbore Columns XTerra® Analytical Columns

ID Length Particle Size Type MS C18

MS C8

RP18

RP8

Phenyl

NEW 3.0 mm 20 mm 2.5 µm IS™ Column 186001972 186001973 — — —3.0 mm 20 mm 2.5 µm Cartridge 1860005884 1860005894 — — —NEW 3.0 mm 20 mm 3.5 µm IS™ Column 186001974 186001975 186001976 186001977 —3.0 mm 20 mm 3.5 µm Guard 1860006404 1860006414 1860006424 1860006434 186001190NEW 3.0 mm 20 mm 5 µm IS™ Column 186001984 186001985 186001986 186001987 —3.0 mm 20 mm 5 µm Guard 1860006564 1860006574 1860006584 1860006594 1860011943.0 mm 30 mm 2.5 µm Column 186000596 186000597 — — —3.0 mm 30 mm 3.5 µm Column 186000412 186000413 — —3.0 mm 50 mm 2.5 µm Column 186000598 186000599 — — —3.0 mm 50 mm 3.5 µm Column 186000414 186000415 186000416 186000417 1860011413.0 mm 50 mm 3.5 µm Cartridge 1860005105 1860005115 1860005125 1860005135 —3.0 mm 50 mm 5 µm Column 186000462 186000463 186000464 186000465 1860011483.0 mm 50 mm 5 µm Cartridge 1860005545 1860005555 1860005565 1860005575 —3.0 mm 100 mm 3.5 µm Column 186000418 186000419 186000420 186000421 1860011423.0 mm 100 mm 3.5 µm Cartridge 1860005145 1860005155 1860005165 1860005175 —3.0 mm 100 mm 5 µm Column 186000466 186000467 186000468 186000469 1860011493.0 mm 100 mm 5 µm Cartridge 1860005585 1860005595 1860005605 1860005615 —3.0 mm 150 mm 3.5 µm Column 186000422 186000423 186000424 186000425 1860011433.0 mm 150 mm 3.5 µm Cartridge 1860005185 1860005195 1860005205 1860005215 —3.0 mm 150 mm 5 µm Column 186000470 186000471 186000472 186000473 1860011503.0 mm 150 mm 5 µm Cartridge 1860005625 1860005635 1860005645 1860005655 —3.0 mm 250 mm 5 µm Column 186000474 186000475 186000476 186000477 1860011513.0 mm 250 mm 5 µm Cartridge 1860005665 1860005675 1860005685 1860005695 —NEW 3.9 mm 20 mm 2.5 µm IS™ Column 186001899 186001897 — — —NEW 3.9 mm 20 mm 3.5 µm IS™ Column 186001900 186001898 186001902 186001901 —3.9 mm 20 mm 3.5 µm Guard 1860006444 1860006454 1860006464 1860006474 186001191NEW 3.9 mm 20 mm 5 µm IS™ Column 186001988 186001989 186001990 186001991 —3.9 mm 20 mm 5 µm Guard 1860006604 1860006614 1860006624 1860006634 1860011953.9 mm 50 mm 3.5 µm Cartridge 1860008175 1860008185 — — 1860012043.9 mm 50 mm 5 µm Cartridge 1860008155 1860008165 — — 1860012033.9 mm 100 mm 3.5 µm Column 186000426 186000427 186000428 186000429 1860011773.9 mm 100 mm 3.5 µm Cartridge 1860005225 1860005235 1860005245 1860005255 —3.9 mm 100 mm 5 µm Column — — — — 1860011833.9 mm 150 mm 3.5 µm Column — — — — 1860011783.9 mm 150 mm 5 µm Column 186000478 186000479 186000480 186000481 1860011843.9 mm 150 mm 5 µm Cartridge 1860005705 1860005715 1860005725 1860005735 —NEW 4.6 mm 10 mm 3.5 µm Guard 1860019274 — — — —NEW 4.6 mm 10 mm 5 µm Guard 1860019204 1860014344 — — —NEW 4.6 mm 20 mm 2.5 µm IS™ Column 186001889 186001890 — — —4.6 mm 20 mm 2.5 µm Cartridge 1860005904 1860005914 — — —NEW 4.6 mm 20 mm 3.5 µm IS™ Column 186001891 186001892 186001893 186001894 —NEW 4.6 mm 20 mm 5 µm IS™ Column 186001992 186001993 186001994 186001995 —4.6 mm 30 mm 2.5 µm Column 186000600 186000601 — — —4.6 mm 30 mm 3.5 µm Column 186000430 186000431 186001910 186001912 —4.6 mm 30 mm 5 µm Column 186000878 186000879 186001909 186001911 —


MS C8

RP18

RP8

Phenyl

75 µm 50 mm 3.5 µm Capillary 186002198 — — — —75 µm 100 mm 3.5 µm Capillary 186002199 — — — —75 µm 150 mm 3.5 µm Capillary 186002200 — — — —100 µm 50 mm 3.5 µm Capillary 186002210 — — — —100 µm 100 mm 3.5 µm Capillary 186002211 — — — —100 µm 150 mm 3.5 µm Capillary 186002212 — — — —150 µm 50 mm 3.5 µm Capillary 186002469 — — — —150 µm 100 mm 3.5 µm Capillary 186002470 — — — —150 µm 150 mm 3.5 µm Capillary 186002471 — — — —300 µm 50 mm 3.5 µm Capillary 186002599 — — — —300 µm 100 mm 3.5 µm Capillary 186002600 — — — —300 µm 150 mm 3.5 µm Capillary 186002601 — — — —300 µm 50 mm 5 µm Capillary 186002602 — — — —300 µm 100 mm 5 µm Capillary 186002603 — — — —300 µm 150 mm 5 µm Capillary 186002604 — — — —1.0 mm 50 mm 2.5 µm Column 186000979 — — — —1.0 mm 50 mm 3.5 µm Column 186000386 186000387 186000388 186000389 —1.0 mm 100 mm 3.5 µm Column 186000390 186000391 186000392 186000393 —1.0 mm 150 mm 3.5 µm Column 186000394 186000395 186000396 186000397 —2.1 mm 10 mm 3.5 µm Guard 1860006321 1860006331 1860006341 186000635

1186001188

2.1 mm 10 mm 5 µm Guard 1860006481 1860006491 1860006501 1860006511

1860011922.1 mm 15 mm 2.5 µm Direct Connect Column 186000900 — — — —NEW 2.1 mm 15 mm 3.5 µm Direct Connect Column 186001908 — — — —NEW 2.1 mm 15 mm 5 µm Direct Connect Column 186001907 — — — —NEW 2.1 mm 15 mm 10 µm Direct Connect Column 186001906 — — — —NEW 2.1 mm 20 mm 2.5 µm IS™ Column 186001921 186001922 — — —NEW 2.1 mm 20 mm 3.5 µm IS™ Column 186001923 186001924 186001925 186001926 —2.1 mm 20 mm 3.5 µm Guard 1860006362 1860006372 1860006382 1860006392 186001189NEW 2.1 mm 20 mm 5 µm IS™ Column 186001979 186001980 186001982 186001983 —2.1 mm 20 mm 5 µm Guard 1860006522 1860006532 1860006542 1860006552 1860011932.1 mm 30 mm 2.5 µm Column 186000592 186000593 — — —2.1 mm 30 mm 3.5 µm Column 186000398 186000399 — —2.1 mm 50 mm 2.5 µm Column 186000594 186000595 — — —2.1 mm 50 mm 3.5 µm Column 186000400 186000401 186000402 186000403 1860011792.1 mm 50 mm 3.5 µm Cartridge 1860004983 1860004993 1860005003 1860005013 —2.1 mm 50 mm 5 µm Column 186000446 186000447 186000448 186000449 1860011852.1 mm 50 mm 5 µm Cartridge 1860005383 1860005393 1860005403 1860005413 —2.1 mm 100 mm 3.5 µm Column 186000404 186000405 186000406 186000407 1860011802.1 mm 100 mm 3.5 µm Cartridge 1860005023 1860005033 1860005043 1860005053 —2.1 mm 100 mm 5 µm Column 186000450 186000451 186000452 186000453 1860011862.1 mm 100 mm 5 µm Cartridge 1860005423 1860005433 1860005443 1860005453 —2.1 mm 150 mm 3.5 µm Column 186000408 186000409 186000410 186000411 1860011812.1 mm 150 mm 3.5 µm Cartridge 1860005063 1860005073 1860005083 1860005093 —2.1 mm 150 mm 5 µm Column 186000454 186000455 186000456 186000457 1860011872.1 mm 150 mm 5 µm Cartridge 1860005463 1860005473 1860005483 1860005493 —2.1 mm 250 mm 5 µm Column 186000458 186000459 186000460 186000461 —2.1 mm 250 mm 5 µm Cartridge 1860005503 1860005513 1860005523 1860005533 —

Needs Guard Holder Part No WAT097958

Needs Cartridge Column Holder Part No 186000262

Needs Cartridge Column End Connector Kit Part No 700000117

Needs Part No WAT046910 (Universal, use with standard columns) or WAT046905 (Integrated into cartridge column)

Needs End Connector Kit Part No WAT037525

Needs 7.8 x 10 mm Cartridge Holder Part No 186000708

Needs 10 x 10 mm Cartridge Holder Part No 289000779

Needs 19 x 10 mm Cartridge Holder Part No 186000709


MS C8

RP18

RP8

Phenyl

4.6 mm 50 mm 2.5 µm Column 186000602 186000603 — — —4.6 mm 50 mm 3.5 µm Column 186000432 186000433 186000434 186000435 —4.6 mm 50 mm 3.5 µm Cartridge 1860005265 1860005275 1860005285 1860005295 —4.6 mm 50 mm 5 µm Column 186000482 186000483 186000484 186000485 1860011444.6 mm 50 mm 5 µm Cartridge 1860005745 1860005755 1860005765 1860005775 —4.6 mm 100 mm 3.5 µm Column 186000436 186000437 186000438 186000439 1860011394.6 mm 100 mm 3.5 µm Cartridge 1860005305 1860005315 1860005325 1860005335 —4.6 mm 100 mm 5 µm Column 186000486 186000487 186000488 186000489 1860011454.6 mm 150 mm 3.5 µm Column 186000440 186000441 186000442 186000443 1860011404.6 mm 150 mm 3.5 µm Cartridge 1860005345 1860005355 1860005365 1860005375 —4.6 mm 150 mm 5 µm Column 186000490 186000491 186000492 186000493 1860011464.6 mm 150 mm 5 µm Cartridge 1860005785 1860005795 1860005805 1860005815 —4.6 mm 250 mm 3.5 µm Column 186001470 186001471 186001472 186001473 1860014744.6 mm 250 mm 5 µm Column 186000494 186000495 186000496 186000497 1860011474.6 mm 250 mm 5 µm Cartridge 1860005825 1860005835 1860005845 1860005855 —

ID (mm) Length (mm) Particle Size Type MS C18

4.6 mm 50 mm 2.5 µm Column 18600060210 mm 50 mm 2.5 µm Column 186000982

ID (mm) Length (mm) Particle Size Type MS C18

MS C8

RP18

RP8

Phenyl

2.1 mm 100 mm 3.5 µm Col MVK Custom 186000831 Custom 186000834 Custom2.1 mm 150 mm 5 µm Col MVK 186000827 Custom Custom Custom Custom3.9 mm 150 mm 5 µm Col MVK 186000828 Custom Custom 186000836 Custom4.6 mm 100 mm 3.5 µm Col MVK Custom 186000832 Custom 186000835 Custom4.6 mm 150 mm 3.5 µm Col MVK 186000826 Custom 186000861 Custom 1860022344.6 mm 150 mm 5 µm Col MVK 186000829 Custom 186000862 Custom 1860022354.6 mm 250 mm 5 µm Col MVK 186000830 186000833 186000863 Custom 186002236

All other Method Validation kits are custom made on request

XTerra® Method Validation Kits

XTerra® Prep Columns

XTerra® Oligonucleotide Purification Columns


MS C8

RP18

RP8

7.8 mm 10 mm 5 µm Cartridge 1860011686 1860011696 1860011706 1860011716

7.8 mm 10 mm 10 µm Cartridge 1860011726 1860011736 1860011746 1860011756

7.8 mm 50 mm 5 µm Column 186001152 186001153 186001154 1860011557.8 mm 100 mm 5 µm Column 186001156 186001157 186001158 1860011597.8 mm 150 mm 5 µm Column 186001475 186001476 186001477 1860014787.8 mm 150 mm 10 µm Column 186001160 186001161 186001162 1860011637.8 mm 300 mm 10 µm Column 186001164 186001165 186001166 18600116710 mm 10 mm 5 µm Cartridge 1860010017 1860010047 1860010067 1860010087

10 mm 10 mm 10 µm Cartridge 1860010027 1860010057 1860010077 1860010097

10 mm 30 mm 5 µm Column 186001010 186001011 186001012 18600101310 mm 50 mm 5 µm Column 186001014 186001015 186001016 18600101710 mm 100 mm 5 µm Column 186001018 186001019 186001020 18600102110 mm 150 mm 5 µm Column 186001479 186001480 186001481 18600148210 mm 150 mm 10 µm Column 186001022 186001023 186001024 18600102510 mm 250 mm 10 µm Column 186001026 186001027 186001028 18600102910 mm 300 mm 10 µm Column 186001030 186001031 186001032 18600103319 mm 10 mm 5 µm Cartridge 1860011048 1860011058 1860011068 1860011078

19 mm 10 mm 10 µm Cartridge 1860010348 1860010358 1860010368 1860010378

19 mm 30 mm 5 µm OBD™ Column 186002383 186002384 186002385 18600238619 mm 50 mm 5 µm OBD™ Column 186001930 186001931 186001932 186001933NEW 19 mm 50 mm 10 µm OBD™ Column 186002254 — — —19 mm 100 mm 5 µm OBD™ Column 186001934 186001935 186001936 18600193719 mm 150 mm 5 µm OBD™ Column 186002379 186002380 186002381 18600238219 mm 150 mm 10 µm OBD™ Column 186002255 186002256 186002257 18600225819 mm 250 mm 10 µm OBD™ Column 186002259 186002260 186002261 18600226219 mm 300 mm 10 µm OBD™ Column 186002263 186002264 186002265 18600226630 mm 50 mm 5 µm OBD™ Column 186001938 186001939 186001940 18600194130 mm 75 mm 5 µm OBD™ Column 186002387 186002388 186002389 18600239030 mm 100 mm 5 µm OBD™ Column 186001942 186001943 186001944 18600194530 mm 150 mm 10 µm OBD™ Column 186002267 186002268 186002269 18600227030 mm 250 mm 10 µm OBD™ Column 186002271 186002272 186002273 18600227430 mm 300 mm 10 µm OBD™ Column 186002275 186002276 186002277 18600227850 mm 50 mm 5µ m OBD™ Column 186002218 186002219 186002220 18600222150 mm 50 mm 10 µm OBD™ Column 186002279 186002280 186002281 18600228250 mm 100 mm 5 µm OBD™ Column 186002222 186002223 186002224 18600222550 mm 150 mm 10 µm Column 186001079 186001080 186001081 18600108250 mm 250 mm 10 µm Column 186001083 186001084 186001085 18600108650 mm 300 mm 10 µm Column 186001087 186001088 186001089 186001090

1.

2.

3.

4.

5.

6.

7.

8.

AUSTRIA AND EXPORT (CENTRAL SOUTH

EASTERN EUROPE, CIS AND MIDDLE EAST)

(43) 1 8771807

AUSTRALIA

(61) 2 9933 1777

BELGIUM

(32) 2 7261000

BRAZIL

(55) 11 5543 7788

CANADA

800 252 4752

CHINA

8610 845 18918

DENMARK

(45) 46 598080

FINLAND

(358) 9 506 4140

FRANCE

(33) 1 30 48 72 00

GERMANY

(49) 6196 40 06 00

HONG KONG

852 2964 1800

INDIA AND INDIA SUBCONTINENT

(91) 80 28371900

IRELAND

(353) 1 448 1500

ITALY

(39) 02 27421.1

JAPAN

(81) 3 3471 7191

KOREA

(82) 2 820 2700

MEXICO

(5255) 5524 76 36

THE NETHERLANDS

31 (0)76-50 87 200

NORWAY

(47) 63 84 60 50

PUERTO RICO

(787) 747 8445

SINGAPORE

(65) 6278 7997

SPAIN

(34) 93 600 93 00

SWEDEN

(46) 8 555 11500

SWITZERLAND

(41) 62 889 2030

TAIWAN(886) 2 2543 1898

UNITED KINGDOM (44) 208 238 6100

ALL OTHER COUNTRIES: WATERS CORPORATION U.S.A. 508 478 2000/800 252 4752

www.waters.com

©2004 Waters Corporation.

All rights reserved. Waters, XTerra, Oasis, OBD, IS, Alliance,Autopurification, NanoEase, Micromass, FractionLynx, ZQ, andQuattro Ultima are trademarks of Waters Corporation. BioCAPis a trademark of Bio-Rad Laboratories.

720000424EN 07/04

Sales Offices

XTerra Columns Bricgure - Waters Corporation · XTerra® MS XTerra ®MS C 18 and MS C 8 columns...

Documents

Transcript of XTerra Columns Bricgure - Waters Corporation · XTerra® MS XTerra ®MS C 18 and MS C 8 columns...